Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The site footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-08T21:36:43.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the usual study record content and blocking access to the study details.
    Difference
    21%
    Check dated 2026-09-24T20:43:54.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The page now shows Revision: v3.7.0 in place of the previous v3.6.6, indicating an updated version of the study documentation within the record. This reflects a metadata update on the study record rather than changes to the trial's substantive details.
    Difference
    0.0%
    Check dated 2026-09-17T21:54:12.000Z thumbnail image
  5. Check
    64 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.4 to v3.6.5, indicating a new version of the page. This change is a metadata/version update and does not modify the reported study details.
    Difference
    0.0%
    Check dated 2026-08-06T20:41:01.000Z thumbnail image
  6. Check
    78 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.3 to v3.6.4 on the page. This reflects a new page version rather than changes to substantive content.
    Difference
    0.0%
    Check dated 2026-07-23T11:56:53.000Z thumbnail image
  7. Check
    100 days ago
    Change Detected
    Summary
    The page shows Revision: v3.6.3, replacing the previous Revision: v3.6.1, indicating a newer version reference for an internal document or component on the page.
    Difference
    0.0%
    Check dated 2026-07-02T03:15:35.000Z thumbnail image

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.